Towa Pharmaceutical
4553.TPharmaceutical
Filed as TOWA PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥273.7bn | ¥259.6bn | ¥227.9bn | ¥208.9bn | ¥165.6bn | ¥154.9bn |
| Operating income | ¥23.1bn | ¥23.2bn | ¥17.6bn | ¥5.5bn | ¥19.2bn | ¥19.9bn |
| Ordinary income | ¥28.1bn | ¥26.2bn | ¥24.5bn | ¥5.1bn | ¥22.7bn | ¥18.7bn |
| Net income (owners) | ¥5.3bn | ¥19.0bn | ¥16.2bn | ¥2.2bn | ¥15.9bn | ¥14.0bn |
| Total assets | ¥475.3bn | ¥470.8bn | ¥430.7bn | ¥371.3bn | ¥332.1bnr | ¥245.7bn |
| Net assets / equity | ¥178.1bn | ¥171.6bn | ¥155.9bn | ¥136.9bn | ¥132.2bn | ¥116.6bn |
| Operating cash flow | ¥30.4bn | ¥23.4bn | ¥8.2bn | ¥2.5bn | ¥22.1bn | ¥12.0bn |
| EPS (basic) | ¥106.66 | ¥385.71 | ¥328.59 | ¥44.72 | ¥323.36 | ¥283.62 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 203 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 206 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | AnnualAmended | 208 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 208 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 48 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 210 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 51 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 75 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 50 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 212 figures · EDINET |
25 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Domestic | ¥217.0bn | ¥27.1bn |
| Overseas | ¥56.7bn | ¥458m |
| Adjustments & eliminations | — | −¥4.5bn |
| Total | ¥273.7bn | ¥27.6bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.